- Press releases

Asceneuron appoints Dr Eric Yuen to the Board of Directors

Asceneuron appoints experienced CNS clinician Dr Eric Yuen to the Board of Directors

- News

Asceneuron proudly sponsors Atypical Parkinsonian Syndromes Workshop

As part of its commitment to neurodegenerative disease research and development, Asceneuron proudly sponsors the Atypical Parkinsonian Syndromes Workshop organised by the International Parkinson and Movement Disorder Society (MDS) in May 17-18, 2019 in Munich, Germany.

- Event

Asceneuron panelist at Anglonordic 2019

Asceneuron will take part in a panel discussion at the Anglonordic conference, on May 9th, 2019 in London.

- Event

Asceneuron to present at the European Life Sciences CEO Forum

Our CEO Dirk Beher will be presenter and panellist at the 12th Annual European Life Sciences CEO Forum & Exhibition, February 25th-26th 2019, in Zurich.

- Press releases

Asceneuron appoints Peter Van Vlasselaer as Chairman

Asceneuron appoints Peter Van Vlasselaer as Chairman

- News

Interview of Dirk Beher, CEO & Founder, at the Biotech Showcase

Dirk Beher, CEO & Founder, was interviewed by Mike Ward (Scrip Pharma Intelligence) at the Biotech Showcase in San Francisco last week.

- Event

Asceneuron to attend the 37th Annual J.P. Morgan Healthcare Conference

Asceneuron will be taking meetings around the 37th Annual J.P. Morgan Healthcare Conference held on January 7-10, 2018 in San Francisco, CA.

- Press releases

Asceneuron appoints Dr. Thomas C. Wessel as Chief Medical Officer

Asceneuron appoints Dr. Thomas C. Wessel as Chief Medical Officer

- Press releases

Asceneuron initiates neuroimaging trial for ASN120290

Asceneuron initiates neuroimaging trial for tau modifier ASN120290

- Event

Asceneuron panelist at BIO-Europe 2018

Asceneuron will take part to a panel discussion at BIO-Europe, on November 5th-7th, 2018 in Copenhagen, Denmark.